
|Videos|September 27, 2016
- Hematologic Malignancies: Polycythemia Vera
- Volume 3
- Issue 3
Significant Developments in Treating PV
Author(s)Srdan Verstovsek, MD, PhD
Srdan Verstovsek, MD, PhD, Chief, Section for Myeloproliferative Neoplasms at the University of Texas MD Anderson Cancer Center, discusses the most recent developments in diagnosing polycythemia vera.
Advertisement
Articles in this issue
about 9 years ago
Differences Between Polycythemia Vera and Essential Thrombocythemiaabout 9 years ago
Experts Debate Need for New Drugs to Treat Patients with PV and ETabout 9 years ago
Management of ET, PV Requires 2 Distinct Approachesabout 9 years ago
Expert Discusses Recent Developments in Polycythemia Veraabout 9 years ago
Ruxolitinib Beats Out Best Available Therapy in Polycythemia VeraAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC
2
Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer
3
T-DXd Plus Pertuzumab Yields Favorable Benefit Over SOC in HER2+ Breast Cancer
4
Giredestrant Improves IDFS vs SOC in ER+/HER2– Early Breast Cancer
5










































